Global regulatory gaps and profit-driven biotech fuel ethical risks of gene therapy, beyond a single Chinese case
Original framing: “The ethical perils of gene therapy” — Financial Times
Scientific evidence shows that off‑target effects, immune reactions, and long‑term ecological impacts remain insufficiently quantified, especially in diverse genetic backgrounds. The rush to market often bypasses robust phase‑III trials, and data sharing across borders is fragmented, limiting meta‑analyses that could reveal systemic risks. Strengthening open‑science pipelines and mandating longitudinal cohort studies would provide the empirical foundation needed for responsible deployment.
The Chinese case of gene‑therapy risk is not an isolated mishap but a symptom of a global biotech ecosystem driven by profit, fragmented regulation, and historical patterns of biopower.
By weaving Indigenous relational ethics, historical eugenic precedents, cross‑cultural moral frameworks, and robust scientific data, we see that the current governance model fails to protect vulnerable populations and ecosystems. Trickster insights destabilize complacent narratives, urging a re‑imagined regulatory architecture that includes a binding UN treaty, community‑led review boards, and an open‑science registry. Equitable access mechanisms and capacity‑building further guard against a new genetic colonialism, aligning innovation with justice and planetary health.